The expression of MR1 was not significantly associated with OS or PFS in any of the above cancers but showed trending p values for worse OS in CRC (p = 0.078 by log-rank test), worse PFS in stomach adenocarcinoma (p = 0.081), and better PFS in prostate adenocarcinoma (p = 0.10). Here, MR1 is linked to cancer.